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SUMMARY
Nosocomial infections are a major challenge for public health because of the high rates of morbidity and mortality
generated. It was considered that the excessive or inappropriate use of antibiotics triggers the emergence of resistant strains.
Among the clinically important bacteria that most commonly cause nososcomial infections, Gram positive multiresistant
pathogens stand out such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus
spp (VRE), and the Gram negative strains of Klebsiella pneumoniae, Escherichia coli, Pseudomonas spp. and Acinetobacter
baumannii producing expanded spectrum β-lactamases (ESβL). This review describes the behavior of the main bacterial
pathogens resistant to antibiotics that cause infections in Europe, United States, and Latin America, emphasizing studies of
molecular epidemiology on a global scale, including the major epidemiological studies in Colombia. The genetic structure
of S. aureus and Enterococcus spp strains shows a clonal characteristic favored by the predominance of a small number of
clones with the capacity to spread globally, due probably to cross-infection. However, the introduction of MRSA strains from
the community encourages genetic diversity, tending to establish a genetic polyclonal endemic structure in places like the
United States. In Gram negative bacteria, the high genetic diversity among isolates, mainly in Latin American countries,
indicates that the polyclonal spread is influenced by horizontal transfer of plasmids, by excessive exposure to antibiotics, and
prolonged hospital stays. In Colombia, there is information on nosocomial resistant pathogens, but molecular epidemiological
information is still scarce.
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Epidemiología de bacterias nosocomiales resistentes a los antimicrobianos
RESUMEN
Las infecciones nosocomiales constituyen un gran desafío para la salud pública por las altas tasas de morbilidad y
mortalidad que generan. Se ha considerado que el uso inapropiado o excesivo de antibióticos desencadena la aparición de
cepas resistentes. Entre las bacterias de importancia clínica que con mayor frecuencia causan infecciones nososcomiales, se
destacan los patógenos Gram positivos multiresistentes como Staphylococcus aureus con resistencia a meticilina (SARM)
y Enterococcus spp. resistentes a vancomicina (ERV). En los Gram negativos, hay resistencia sobre todo con las cepas de
Klebsiella pneumoniae, Escherichia coli, Pseudomonas spp. y Acinetobacter baumannii productoras de β-lactamasas de
espectro extendido (BLEEs, en inglés: ESβL expanded spectrum β-lactamases). Esta revisión tiene como finalidad realizar
una decripción del estado de la resistencia bacteriana a los antibióticos en los principales patógenos que causan infecciones
nosocomiales en países de Europa, Estados Unidos y de Latinoamérica, destacando los estudios de epidemiología molecular
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a escala global e incluyendo los principales estudios
epidemiológicos realizados en Colombia. La estructura
genética de las cepas de Staphylococus aureus y Enterococcus
spp. evidencia una característica clonal favorecida por el
predominio de un número pequeño de clones con capacidad
de diseminarse en forma global, debida probablemente a
infecciones cruzadas. Sin embargo, la introducción de cepas
SARM desde la comunidad está favoreciendo la diversidad
genética, tendiendo a establecerse una estructura genética
policlonal en lugares endémicos como los Estados Unidos.
En las bacterias Gram negativas, se destaca una alta diversi-
dad genética entre los aislados, sobre todo en países de
Latinoamérica, indicando que la diseminación sigue una
estructura genética policlonal, influida por la transferencia
horizontal de plasmidos, por la excesiva exposición a
antibióticos y una estancia hospitalaria prolongada. En Co-
lombia se dispone de información sobre los patógenos
nosocomiales resistentes, pero la información epidemiológica
molecular aún es escasa.
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Currently, studies on epidemiology surveillance
report increased bacterial resistance to antimicrobial
agents and their association with nosocomial infection,
contributing to greater morbidity and mortality rates1.
The nosocomial pathogens reported with the highest
rates of resistance correspond to Gram-positive
organisms like methicillin-resistant Staphylococcus
aureus (MRSA). When vancomycin was introduced,
the MRSA strains acquired resistance to this antibiotic,
now denominated Vancomycin-Resistant Staphylo-
ccocus aureus2 (VRSA). Coinciding with this circums-
tance, the first strains of vancomycin-resistant
Enterococcus spp. (VRE) appeared; now widely
distributed worldwide3.
In Gram-negative bacilli, resistance is given mainly
by β-lactamase enzimes classified into two important
groups: expanded spectrum β-lactamases (ESβL),
codified in megaplasmids, and the inducible
chromosomal β-lactamase4. The strains with ESβLs
are reported mainly in Klebsiella pneumoniae,
Escherichia coli, Proteus mirabilis, and other species
like Enterobacter sp. and Citrobacter freundii,
becoming an important health problem, which has
rapidly increased and spread throughout the world5.
Moreover, chromosomal β-lactamase is described in
nonfementing Gram-negative bacilli like Citrobacter
spp., Enterobacter spp., Serratia spp., Providencia
spp., Pseudomonas spp., and Acinetobacter  baumannii.
These bacteria are grouped under the acronym SPACE
(S: Serratia; P: Pseudomonas; A: Acinetobacter; C:
Citrobacter; E: Enterobacter). The greatest state of
resistance in this group is principally reported in
multidrug-resistant Pseudomonas aeruginosa and
Acinetobacter spp.  (MDRs)5,6.
The state of world resistance of nosocomial patho-
gens, and of those appearing in community, is monitored
by different surveillance programs, among which is the
SENTRY program incorporating molecular typification
of strains and the genotypification of the resistance as
a mechanism of additional information, which permits
following the world distribution of pathogenic micro-
organisms, within the denominated molecular epide-
miology. Some of the molecular techniques used in this
type of analysis include: ribotyping, genomic analysis
of the amplified fragment length polymorphism (AFLP),
pulsed field gel electrophoresis (PFGE), random
amplification of polymorphic DNA (RAPD), arbitrary
primed polymerase chain reaction (AP-PCR), ampli-
fication of repetitive element sequence-based PCR
(rep-PCR), and multilocus sequence typification
(MLST)7.
This review will address epidemiological studies
reporting the state of antimicrobial resistance in
nosocomial pathogens in developed nations like the
United States and some European nations, in contrast
with Latin American nations including Colombia.
State of antimicrobial resistance in the world.
Worldwide, the state of resistance increased consi-
derably in Gram-positive and Gram-negative pathogens.
Reports indicate that among Gram-positive organisms
S. aureus is one of the pathogens with the tendency to
more quickly acquire resistance. This bacterium whose
resistance has reached worldwide epidemic proportions,
is naturally susceptible to most antibiotics developed.
Resistance is often acquired by horizontal transfer of
external origin genes, chromosomal mutation, and
antibiotic selection. Most diseases produced by this
bacterium are caused by MRSA strains, which have
been on the rise in many countries both at the community
level and hospitals2.
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In England, there are reports of increased proportion
of MRSA isolates since 1990 at 2%, reaching its
maximum peak at 43% in 20028. In spite of the contention
measures taken to diminish spread of the pathogen, by
the end of 2010, MRSA epidemic outbreaks continue to
be reported9. The epidemiological state of MRSA in
other European nations registers similar behavior. In
Spain, the MRSA strains have presented a notable
increase in nosocomial infections in recent years10.
However, in other countries the measures to control the
spread of MRSA strains have had a positive effect; thus,
for example, Denmark reports cases of MRSA infections
since the 1970s, mortality in cases of bacteremia
diminished notably until the year 200011.
In Asian nations like Japan, cases of patients
developing infections through MRSA were 35.8%
during the start of the decade of 200012. According to
epidemiological studies, in the United States the MRSA
strains presented a 32.4% rate of occurrence during
1997 and 200213. For 2004 and 2005, the prevalence
increased dramatically, favored by the spread of the
strains in the community14.
For other Gram-positive bacteria, epidemiological
surveillance systems indicate that the recurrence and
spread of antibiotic resistant Enterococcus present
differences between geographic areas3. According to
the 2002 annual report by the European surveillance
system (http//:www.earss.rivm.nl), the prevalence of
ampicillin-resistant Enterococcus faecium strains
reached rates up to 10% in six European countries. This
increase was even greater in some countries like
Denmark15. Nevertheless, the epidemiological pattern
changed during the last eight years, when resistance to
vancomycin became evident in some ampicillin-resistant
Enterococcus strains3. Resistance to vancomycin is
mainly determined by the acquisition of transposons,
with high power to spread among strains with different
genetic determinants16. For the first decade of 2000, a
high occurrence rate of VRE infections was registered
in countries like Spain17.
In Asia, the VRE strains have been isolated from
patients hospitalized and from the community, mainly
in countries like Japan18 and South Korea19. The
introduction of the pathogen into the community was
primarily due to the consumption of contaminated
meats18,19. In the United States, as in Europe, public
health problems generated by Enterococcus are
influenced by the recurrence of vancomycin-resistant
nosocomial Enterococcus faecium outbreaks during
the decade of 20003. Epidemiological reports of Gram-
negative bacteria point to bacteria from the family of
ESβL-producing Enteobacteriaceae, as the main
generators of nosocomial infections4.
An important presence of ESβL producing K.
pneumoniae strains was reported in Southern and
Western Europe during the late 1990´s20. The presence
of these strains is still being reported during this decade
in hospital wards in Italy21. In Spain, epidemiological
records reveal that the participation of ESβL producing
strains has been maintained in nosocomial infections;
but with a preoccupying extension to the community22.
The presence of these strains in the community is
reported in other countries like Poland, France, and the
United Kingdom, among others23.
The epidemiological behavior of ESβL producing
K. pneumoniae has generated serious public health
problems in Asian nations like China24, in African
nations25, and in the American continent, especially in
the United States26.
Ever since the determination of the presence of
ESβLs for the first time in E.coli strains in Europe, the
frequency of these strains transporting these resistance
determinants has been kept high, as indicated by
epidemiological reports in Spain27 and France28.
In the United States, during the last decade, the
presence of ESβL producing E. coli strains in hospitals
in different states29, with a preoccupying increase in the
community30.
When studying the epidemiological behavior of
nonfementing enterobacteria, we found that the situation
worsens and particularly with A. baumannii because
this pathogen plays an important function in coloni-
zation and infection of patients, especially those
Intensive Care Units (ICU) of hospitals worldwide31,32.
Effective treatment against infections caused by A.
baumannii was via carbapenem; however, resistance to
this class of β-lactam antibiotic is now habitual31.
Similar results were obtained with the use of other
potentially effective antibiotics against A. baumannii
like tetracyclines, last generation aminoglycosides, and
sulbactam32.
The emergence of strains simultaneously resistant
to three drugs, introduced the epidemiological term of
multiresistance and resistance to all panresistance31-33.
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The presence of multiresistant strains in some European
and Asian nations constitutes a serious public health
problem34; the situation turns more alarming with the
emergence of multiresistant and panresistant A.
baumannii strains31,33.
Multiresistant strains often spread and cause
epidemic outbreaks in entire cities, countries, and
continents34. The exchange of multiresistant strains
between continents has been demonstrated, as evidenced
by a study on molecular epidemiology, which determined
the presence of multiresistant A. baumannii clones in
hospitals in the United States and Europe, but with
different genetic determinants35. Nonetheless, the
existence of identical clones has been identified in
military and civilian personnel from the United States
and the United Kingdom who had returned from
operations in Afganistan and Irak36,37.
Antimicrobian resistance in nosocomial pathogens
in the world reveals greater prevalence of Gram-positive
bacteria in Europe, especially MRSA strains. In contrast,
the United States presents similarities in the presence of
Staphylococcus spp., Enterococcus spp., and non-
fementing Gram-negative organisms. These results show
the need for implementing government policies in inte-
gral health, which permit a better quality of life, involve
nutritional conditions, adequate administration of wastes
and of chemotherapeuticals, as applied in several
European countries in recent years.
State of resistance in Latin America. The first
reports of resistance in nosocomial infections were
made in Argentina and Brazil in the late 1990s38.
Reports in Latin America indicate that MRSA strains
bear epidemiological importance in Mexican hospitals,
as revealed by epidemiological studies conducted from
1997 to 200339 and in Venezuela in 2005, where the
MRSA strains also signaled resistance to oxacilin,
gentamicin, erythromycin, and tobramycin and in 93%
of the cases it was due to the presence of the mecA
gene40. In Asunción, Paraguay, the prevalence of MRSA
strains corresponded to 43.8%41 and in several cities in
Argentina, especially in Córdoba with a 37% preva-
lence42.
In spite of the great epidemiological relevance of S.
aureus in Latin American nations, cases of infection
due to VRE are reported in hospitals in Argentina43,
Chile44, and Perú45. Among Gram-positive bacteria,
those most frequently reported causing nosocomial
infections correspond to ESβL producing E. coli in
Chile, Argentina, Brazil46, Perú, and Bolivia47. The K.
pneumoniae strains turned out to be ESBL producing
by 27.6% in Mexico and by 47.5% in Brazil46. In Chile,
it is reported that poor use of antibiotics like ceftriaxone
was important in promoting the spread of ESβL
producing K. pneumoniae strains48.
The presence of multiresistant A. baumannii has
generated serious public health problems with reports
of epidemic outbreaks in hospitals in Argentina49 and,
according to SENTRY, in hospitals of Brazil, Chile,
and Uruguay50, among other countries.
The principal studies on resistance of nosocomial
bacteria have been conducted in Argentina, Brazil, and
Chile. According to reports, it was observed that the
highest resistance rates among MRSA strains exist in
Venezuela, while for Argentina, Brazil, México, Perú,
and Bolivia resistance is most alarmingly registered in
the Enterobacteriaceae family, with a special tendency
in the propagation of A. baumannii. However, there is
a lower distribution in resistance measured for ESβLs
in southern cone Latin American nations, especially
enteropathogens like E. coli and K. pneumoniae. In
contrast, we observed greater resistance tendency in
countries like México and Brazil for these same
pathogens. For Enterobacter spp. a tendency to
diminished resistance was observed in recent years,
primarily in Southern hemisphere nations.
State of resistance in Colombia. Epidemiological
studies conducted in Bogotá by Álvarez et al. 51, in early
2000 reveal predominance of bacteria from the
Enterobacteriaceae family, with a 34% prevalence for
K. pneumoniae, 37% for P. aeruginosa, and 38% for A.
baumannii, these last are imipenem resistant. In another
study conducted in 2002 and 2003, the most frequent
nosocomial microorganisms corresponded to S. aureus
at 24%, E. coli at 18%, P. aeruginosa at 9%, A.
baumannii at 6%52. A molecular epidemiology study of
ESBL producing strains determined the significant
presence of K. pneumoniae53, with the prevalence of a
unique clone in hospitals in different cities54.
In 2006, a molecular study was conducted on metalo-
β-lactamase (MβL) producing A. baumannii strains in
clinical isolates in Intensive Care Units at hospitals in
Bogotá55. The data obtained by the CIDEIM group in
2004, including several hospitals in Colombia, report
the presence of imipenem-resistant A. baumannii and
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P. aeruginosa56.
Among the resistance observed in the Gram-positive
cocci, the MRSA strains showed resistance rates
between 24% and 48% in studies carried out in hospitals
of Bogotá57; these data are similar to those recorded in
Paraguay with a predominant clone. Data reported for
VRE revealed low prevalence. Toward more populated
zones in our country, we observed a high percentage of
resistance in ESβL producing Gram-negative bacteria.
For Enterobacter spp. strains, we observed a greater
rate of resistance in cities in the Atlantic Coast. In the
Andean region and in the Atlantic Coast, we noted a
high percentage of resistance in bacteria like P.
aeruginosa and  A. baumannii.
Molecular epidemiology of nosocomial bacteria.
Global epidemiology of the state of resistance in
nosocomial bacteria is variable and it is very much
related to policies in each nation. Thus, for example,
when analyzing the genetic structure of the Enterococcus
spp. resistant population the greatest prevalence is
registered in the United States, reaching endemic
situations with clonal dispersion3. However, this charac-
teristic has changed in recent years, favored by the
introduction of endemic strains from the community
onto the hospital environment with new resistance
determinants, generating a polyclonal dispersion
tendency as observed in Europa17. Although the
incidence rate of VRE infection at the intrahospital
level is low, the high frequency of colonization at the
community level is perhaps favored by the introduction
of resistant strains through the consumption of farm
animals as evidenced by some rerorts18,19.
In the analysis of the VRE world population structure
were identified 55 sequence types (ST) with 4 clonal
complexes (CC2, CC9, CC10, CC21); complexes
denominated CC2 and CC9 are the most frequent and
circulate primarily in Central Europe and America3,17.
For MRSA strains, large-scale population genetics
studies published in 1999 and 2000, identified five
clonal complexes or pandemics: Iberian Clone, Brazilian
Clone, Hungarian Clone, New York/Japan Clone, and
Pediatric Clone58.
Current epidemiological studies have demonstrated
that the pediatric clone is the most frequent with
resistance to β-lactam antibiotics; this clone has been
identified in isolates from Poland, the United States,
Argentina, and Colombia. Some researchers suggest
that because of their stability over time and their great
power to spread throughout the continents it may be the
oldest MRSA clone59. The second clone with great
power to spread is the Iberian clone found in isolates
from several European countries, mainly Portugal,
Spain, as well as the United States, where it has been
identified in New York city hospitals14. The New York/
Japan clone is highly predominant in Asian nations12.
The first molecular work to determine MRSA clones
in Latin America was done in 2001, finding that the
Brazilian clone was present in 79% of the strains in
Argentina, Chile, and Uruguay38. In Brazil, intrahospital
infections caused by Staphylococcus spp corresponded
to 80% to 90% through MRSA and all the strains with
the Brazilian clone profile. The pediatric clone was
detected in Paraguay41, Argentina42, Chile46, and Co-
lombia57. México registered strains sharing the New
York clone profile and a group of strains with a unique
diversity classified as M clone39.
Disemination of an MRSA resistant clone among
Latin America countries including Chile, Paraguay,
Argentina, and Brazil was detected in the late 1990s38.
It was, thereafter, confirmed by studies conducted by
Sader et al.46, in 2000.
The population genetics study of Gram-negative
bacteria with ESβLs shows a high diversity, as with K.
pneumoniae and E. coli strains21,22,26-28. Some studies
reveal clonal dispersion for the population of K.
pneumoniae and E. coli26,27. The study conducted by
Deshpande et al.60 in 2004 determined that the ribotypes
identified in the ESβL producing strains from Europe,
the United States, and Latin America were restricted to
one continent or to one country in particular, except for
a clone from the United States and Europe with a shared
pattern. Pattern similar results were obtained from
analysis done on MDR K. pneumoniae strains isolated
from epidemic outbreaks in different hospitals in
European countries, the data reveal great variability in
the resistance patterns, but they all belonged to the same
clone21. The variation was because the resistance
measured via diverse mechanisms like: integrons
transporting the aadB gene (which confers resistance to
gentamicin); in other strains because of the presence of
the aadA gene (which confers resistance to strepto-
mycin), or to the presence of both genes in a trans-
poson5,24,25. In all the strains analyzed, a mutation was
determined in the gyrA gene, which confers resistance
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to ciprofloxacin and the presence of the SHV-5 gene in
the resistance mediated by ESβLs61.
In the population structure of the E. coli strains, we
noted similar behavior to K. pneumoniae. We found that
the β-lactamase producing E. coli strains in hospitals in
Paris was a clone that was primarily spread, according to
findings in a hospital in Tunisia and in the Central African
Republic28. Researchers suggest that the spread was pro-
bably due to characteristic of the clone, with an extra-
ordinary tendency to colonizing or via horizontal transfer
of plasmids on mosaics transporting the resistance gene28.
In Latin America, there are studies of E. coli
population genetics in Brazil conducted by Martins-
Loureiro et al.62, in 2001, who found 6 clones in a group
of 42 epidemiologically related strains, with 9 PFGE
profiles of resistance to the antimicrobial (A-I). The
most frequent clones were: A with 5 profiles, B with 3
profiles and D with 5 profiles. According to the profiles
and to the isolation periods, clones A, A1, B, and D
caused three outbreaks during the study period.
In Colombia, molecular epidemiology studies have
evidenced similar behavior to that registered in the rest
of the Latin American nations; thus, for example, the
molecular characterization of K. pneumoniae with
ESβLs obtained from patients in a third-level hospital
in Bogotá revealed that the genetic variability was
related to nosocomial infections of endogenous origin
rather than cross infections53,54. In this analysis, the
isolates were grouped by PFGE and REP-PCR into 11
and 12 electrophoretic patterns, respectively54. In studies
published by Espinal et al.53, in 2004, it was shown that
all K. pneumoniae isolates were ESβL producers and
the genotyping by PFGE and BOX-PCR grouped two
isolates from hospital environments, as well as eight
isolates that caused infection in an epidemic clonal
group. The isolate from a thermometer was not asso-
ciated to the epidemic clonal group and revealed a
different resistance pattern.
The estate of molecular epidemiology of non-
fermenting pathogens shows increased prevalence of
infections due to resistant strains. In the United States,
the most frequent P. aeruginosa and A. baumannii
clonal outbreaks have been detected in cities like New
York with a ribotype identical to one reported in Spain,
but with a different PFGE pattern35. Likewise, common
clones have been identified in isolates from the United
States and the United Kingdom36,37. These studies
demonstrate that in Latin American nations, the
resistance pattern is more widespread, with MDR strains
predominating as principal etiological agents for noso-
comial infection that are gaining importance in commu-
nity-type infections49,50,55.
Regarding the population structure of A. baumannii,
there are important studies like those conducted in
European hospitals during the early part of the 2000
decade, which identified a great diversity of clones
specifically resistant to polimyxin β, aminocycline,
imipenem, rifampin, sulbactam, meropenem, amikacin,
and doxycycline34. In Latin American countries, the
most important studies on this pathogen are reported in
Argentina where it has been determined that A.
baumannii strains resistant to carbapenems with shared
profile with a clone isolated in Israel49.
In studies carried out in Colombia, much work was
done on molecular characterization during 2003 and
2004 in nosocomial isolates among which there is A.
baumannii, which caused an epidemic outbreak in a
hospital in Bogotá and the determination of associated
factors. In this study, it was determined that the isolates
were resistant to multiple antibiotics and were
genetically related with a similarity percentage greater
than 97%52. In studies done by Pinzón et al.55, in 2006,
9 (A-1) groups were identified; the E group was made
up of 39.2% of the isolates and a clone comprising three
environmental isolates and two recovered from patients.
Molecular epidemiology studies on Gram-positive
pathogens evidence the predominance of a small number
of clones responsible for Staphylococcal infection
throughout the world, i.e., they are able to diseminate
globally (pandemic MRSA clones), probably favored
by cross infections with strains closely related among
hospitals and distant locations.
In Gram-negative bacteria, the high genetic diversity
among the isolates of the enterobacteria, primarily in
Latin American countries, indicates that disemination
is polyclonal in the hospital environment, influenced by
the horizontal transference of plasmids among different
strains, which are under high selective pressure by
broad-spectrum antibiotics. For fermenting entero-
bacteria with resistance mediated by ESβLs, polyclonal-
type dispersion is established characterized by high
genetic diversity, perhaps associated to the selection of
resistant organisms caused by excessive exposure to
antibiotics and prolonged hospital stays.
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PERSPECTIVES
In Latin America, bacterial resistance in hospitals
presents a high variety with small differences among
countries, including Colombia. Nevertheless, molecular
epidemiology studies conducted until now in the country
have been limited to some regions; it is necessary to
carry out a nationwide population genetics study
integrating nosocomial pathogens from different places,
including greater impact Gram-positive organisms like
MRSA strains, and among the Gram-negative orga-
nisms, fermenting enteric bacteria like K. pneumoniae
and E. coli, and non-fermenting bacteria, especially A.
baumannii, which has currently become a serious
morbidity and mortality problem in the country. It is
necessary to determine if the microorganism follows a
behavior similar to that observed in other Latin American
nations and its genetic relationship with strains circula-
ting in other regions of the world.
The use of molecular epidemiology in the study of
nosocomial infections has been fundamental for the
formulation and evaluation of control measures, for the
purpose of diminishing the propagation of resistant
clones. With this strategy, we are able to determine the
factors contributing to the epidemic superiority of the
clones, the surpisingly high level of expression of
certain virulence genes, and their survival ability in the
environment. These factors are important in adopting
measures to control the dispersion of resistant pathogens
and avoid the emergence of strains with greater degrees
of resistance and pathogenicity.
REFERENCES
1. Jones RN. Pathogens: Trends over the past few years resistance
patterns among nosocomial. Chest. 2001; 119: 397-404.
2. Chambers HF, DeLeo FR. Waves of resistance: Staphylococcus
aureus in the antibiotic era. Nat Rev Microbiol. 2009; 7: 629-
41.
3. Leavis HL, Bonten MJ, Willems RJ. Identification of high-
risk enterococcal clonal complexes: global dispersion and
antibiotic resistance. Curr Opin Microbiol. 2006; 9: 454-60.
4. Schwaber MJ, Navon-Venezia S, Schwartz D, Carmeli Y.
High levels of antimicrobial coresistance among extended-
spectrum-α-lactamase-producing Enterobacteriaceae.
Antimicrob. Agents Chemother. 2005; 49: 2137-9.
5. Thomson KS, Smith ME. The new α-lactamases of Gram-
negative bacteria at the dawn of the new millennium. Microb
Infect. 2000; 2: 1225-35.
6. Riccio ML, Franceschini N, Boschi L, Caravelli B, Cornaglia
G, Fontana R, et al. Characterization of the metallo-α-lactamase
determinant of Acinetobacter baumannii AC-54/97 reveals
the existence of bla (IMP) allelic variants carried by gene
cassettes of different phylogeny. Antimicrob Agents
Chemother. 2000; 44: 1229-35.
7. Fluit ADC, Visser MR, Schmitz FJ. Molecular detection of
antimicrobial resistance. Clin Microbiol Rev. 2001; 14: 836-
71.
8. Johnson AP, Duckworth G, Pearson A. Surveillance and
epidemiology of MRSA bacteraemia in the UK. J Antimicrob
Chemother. 2005; 56: 455-62.
9. Pearson A, Chronias A, Murria M. Voluntary and mandatory
surveillance for methicillin-resistant Staphylococcus aureus
(MRSA) and methicillin-susceptible S. aureus (MSSA)
bacteraemia in England. J Antimicrob Chemother. 2009; 64
(Supl 1): i11–i17.
10. Argudín MA, Mendoza MC, Méndez FJ, Martín MC, Guerra
B, Rodicio MR. Clonal complexes and diversity of exotoxin
gene profiles in methicillin-resistant and methicillin-suscepti-
ble Staphylococcus aureus isolates from patients in a Spanish
hospital. J Clin Microbiol. 2009; 47: 2097-105.
11. Benfield T, Espersen F, Frimodt-Moller N, Jensen AG, Larsen
AR, Pallesen LV, et al. Increasing incidence but decreasing
in-hospital mortality of adult Staphylococcus aureus
bacteraemia between 1981 and 2000. Clin Microbiol Infect.
2007; 13: 257-63.
12. Benquan W, Yingchun T, Kouxing Z, Tiantuo Z, Jiaxing Z,
Shuqing T. Staphylococcus heterogeneously resistant to
vancomycin in China and antimicrobial activities of imipenem
and vancomycin in combination against It. J Clin Microbiol.
2002; 40: 1109-12.
13. Biedenbach DJ, Moet GJ, Jones RN. Occurrence and
antimicrobial resistance pattern comparisons among blood-
stream infection isolate from de SENTRY antimicrobial
survillence programs (1997-2002). Diagn Microbiol Infect
Dis. 2004; 50: 59-69.
14. Kennedy AD, Otto M, Braughton KR, Whitney AR, Chen L,
Mathema B, et al. Epidemic community-associated methicillin-
resistant Staphylococcus aureus: Recent clonal expansionand
diversification. Proc Natl Acad Sci USA. 2008; 105: 1327-32.
15. Lester CH, Sandvang D, Olsen SS, Schonheyder HC, Jarlov
JO, Bangsborg J. Emergence of ampicillin-resistant
Enterococcus faecium in Danish hospitals. J Antimicrob
Chemother. 2008; 62: 1203-6.
16. Schouten MA, Willems RJL, Kraak WAG, Top J, Hoogkamp-
Korstanje JAA, Voss A. Molecular analysis of Tn1546-like
elements in vancomycin-resistant enterococci isolated from
patients in Europe shows geographic transposon type
clustering. Antimicrob Agents Chemother. 2001; 45: 986-9.
17. Coque TM, Willems RJ, Fortun J, Top J, Diz S, Loza E, et al.
Population structure of Enterococcus faecium causing
bacteremia in a spanish university hospital: setting the scene
for a future increase in vancomycin resistance? Antimicrob
Agents Chemother. 2005; 49: 2693-700.
18. Ozawa Y, Tanimoto K, Nomura T, Yoshinaga M, Arakawam
Y, Ike Y. Vancomycin-resistant enterococci in humans and
imported chickensin Japan. Appl Environ Microbiol. 2002;
124
Colombia Médica                  Vol. 42 Nº 1, 2011 (Enero-Marzo)
68: 6457-61.
19. Yu HS, Seol SY, Cho DT. Diversity of Tn1546-like elements
in vancomycin-resistant enterococci isolated from humans
and poultry in Korea. J Clin Microbiol. 2003; 41: 2641-3.
20. Babini GS, Livermore DM. Antimicrobial resistance amongs
Klebsiella spp. colleted from intensive care units in Southern
and Western Europe in 1997-1998. J Antimicrob Chemother.
2000; 45: 183-9.
21. Bagattini M, Crivaro V, Di Popolo A, Gentile F, Scarcella A,
Triassi M, et al. Molecular epidemiology of extended-spectrum
α-lactamase-producing Klebsiella pneumoniae in a neonatal
intensive care unit. J Antimicrob Chemother. 2006; 57: 979-
82.
22. Valverde A, Coque TM, García-San Miguel L, Baquero F,
Canto R. Complex molecular epidemiology of extended-
spectrum α-lactamases in Klebsiella pneumoniae: a long-term
perspective from a single institution in Madrid. J Antimicrob
Chemother. 2008; 61: 64-72.
23. Livermore DM, Canton R, Gniadkowsk M, Nordmann P, Rosso-
lini GM, Arlet G, et al. CTX-M: changing the face of ESβLs
in Europe. J Antimicrob Chemother. 2007; 59: 165-74.
24. Wei ZQ, Du XX, Yu YS, Shen P, Chen YG, Li LJ. Plasmid-
mediated KPC-2 in a Klebsiella pneumoniae isolate from
China. Antimicrob Agents Chemother. 2007; 51: 763-76.
25. Gangoue-Pieboji J, Miriagou V, Vourli S, Tzelepi E, Ngassam
P, Tzouvelekis LS. Emergence of CTX-M-15-producing
enterobacteria in Cameroon and characterization of a blaCTX-
M-15-carrying element. Antimicrob Agents Chemother. 2005;
49: 441-3.
26. Kitchel B, Rasheed K, Patel JB, Srinivasan A, Navon-Venezia
S, Carmeli Y, et al. Molecular epidemiology of KPC-producing
Klebsiella pneumoniae isolates in the United States: clonal
expansion of multilocus sequence type 258. Antimicrob Agents
Chemother. 2009; 53: 3365-70.
27. Blanco M, Alonso MP, Nicolas-Chanoine MH, Dahbi G,
Mora A, Blanco JE, et al. Molecular epidemiology of
Escherichia coli producing extended-spectrum α-lactamases
in Lugo (Spain): dissemination of clone O25b:H4-ST131
producing CTX-M-15. J Antimicrob Chemother. 2009; 63:
1135-41.
28. Lavollay M, Mamlouk K, Frank T, Akpabie A, Burghoffer B,
Redjeb S, et al. Clonal dissemination of a CTX-M-15-β-
lactamase-producing Escherichia coli strain in the Paris area,
Tunis, and Bangui. Antimicrob Agents Chemether. 2006; 50:
2433-8.
29. Smith ME, Black JA, Hossain A, Hanson ND, Thomson KS,
Pottumarthy S. Discovery of CTX-M-like extended-spectrum
α-lactamases in Escherichia coli isolates from five US States.
Antimicrob Agents Chemother. 2003; 47: 2382-3.
30. Pitout JDD, Nordmann P, Laupland KB, Poirel L. Emergence
of Enterobacteriaceae-producing extended-spectrum β-
lactamases (ESβLs) in the community. J Antimicrob
Chemother. 2005; 56: 52-9.
31. Hsueh PR, Teng LJ, Chen CY, Chen WH, Yu CJ, Ho SW, et
al. Pandrug-resistant Acinetobacter baumannii causing
nosocomial infections in a university hospital, Taiwan. Emerg
Infect Dis. 2002; 8: 827-32.
32. Rice LB. Challenges in identifying new antimicrobial agents
effective for treating infections with Acinetobacter baumannii
and Pseudomonas aeruginosa. Clin Infect Dis. 2006; 43
(Suppl 2): S100-5.
33. Houang ET, Chu YW, Leung CM, Chu KY, Berlau J, Ng KC,
et al. Epidemiology and infection control implications of
Acinetobacter spp. in Hong Kong. J Clin Microbiol. 2001; 39:
228-34.
34. Van Dessel H, Dijkshoorn L, van der Reijden T, Bakker N,
Paauw A, van den Broek P, et al. Identification of a new
geographically widespread multiresistant Acinetobacter
baumannii clone from European hospitals. Res Microbiol.
2004; 155: 105-12.
35. Quale J, Bratu S, Landman D, Heddurshetti R. Molecular
epidemiology and mechanisms of carbapenem resistance in
Acinetobacter baumannii endemic in New York City. Clin
Infect Dis. 2003; 37: 214-20.
36. Jones A, Morgan D, Walsh A, Turton J, Livermore D, Pitt T,
et al. Importation of multidrug-resistant Acinetobacter spp.
infections with casualties from Iraq. Lancet Infect Dis. 2006;
6: 317-8.
37.  Turton JF, Kaufmann ME, Gill MJ, Pike R, Scott PT, Fishbain
J, et al. Comparison of Acinetobacter baumannii isolates from
the United Kingdom and the United States that were associated
with repatriated casualties of the Iraq conflict. J Clin Microbiol.
2006; 44: 2630-4.
38. Aires De Sousa M, Miragaia M, Santos I, Avila S, Adamson
I, Casagrande S, et al. Three year assesment of methicillin-
resistant Sthaphyloccus aureus clones in Latin America from
1996 to 1998. J Clin Microbiol. 2001; 39: 2197-205.
39. Velázquez MME, Aires de Sousa M, Echaniz AG, Solorzano
SF, Miranda NG, Silva SJ, et al. Surveillance of methicillin-
resistant Staphylococcus aureus in a pediatric hospital in
Mexico City during a 7-year period (1997 to 2003): Clonal
evolution and impact of infection control. J Clin Microbiol.
2004; 42: 3877-80.
40. Velazco E, Nieves B, Araque M, Calderas Z. Epidemiología
de Staphylococcus aureus en una unidad de alto riesgo neonatal.
Enferm Infecc Microbiol Clin. 2002; 20: 321-5.
41. Mayor L, Ortellado J, Menacho C, Lird G, Courtier C, Gardon
C, et al. Molecular characterization of methicillin-resistant
Staphylococcus aureus isolates collected in Asunción, Para-
guay. J Clin Microbiol. 2007; 45: 2298-300.
42. Sola C, Cortés P, Saka HA, Córdoba MRSA Collaborative
Study Group, Vindel A, Bocco JL. Evolution and molecular
characterization of methicillin-resistant Staphylococcus aureus
epidemic and sporadic clones in Cordoba, Argentina. J Clin
Microbiol. 2006. 44: 192-200.
43. Ponessa A, Gambande T, All L. Enterococos vancomicina
resistentes: colonización en pacientes hospitalizados, en Ro-
sario, Argentina. Acta Bioquim Clin Latinoam. 2006; 40: 499-
502.
44. Marovac J, Campos MI. Enterococcus faecium resistente a
vancomicina. Rev Med Chile. 2000; 128: 685-6.
45. Velásquez J, Lizaraso F, Zetola N, Pamno O, Sánchez L,
Wong W, et al. Vigilancia de la resistencia de enterococcus sp
a la vigilancia y evaluacion in vitro de nuevas alternativas
terapéuticas. Rev Soc Peru Med Int. 2002; 15: 1-5.
46. Sader HS, Gales AC, Casellas JM, Smayevsky J, Prado V,
125
Colombia Médica                         Vol. 42 Nº 1, 2011 (Enero-Marzo)
Palaveccino E, et al. Comparison of the antimicrobial
susceptibilities of nosocomial bacteria among Latin American
countries. Intersci Conf Antimicrob Agents Chemother. 2000;
20: 40-85.
47. Pallecchi L, Malossi M, Mantella A, Gotuzzo E, Trigoso C,
Bartoloni A, et al. Detection of CTX-Mtype α-lactamase
genes in fecal Escherichia coli from healthy children in
Bolivia and Peru. Antimicrob Agents Chemother. 2004; 48:
4556-61.
48. Díaz P, Bello H, Domínguez M, Trabal N, Mella S, Zemelman
R, et al. Resistencia a gentamicina, amikacina y ciprofloxacina
en cepas hospitalarias de Klebsiella pneumoniae subespecie
pneumoniae productoras de α-lactamasas de espectro exten-
dido. Rev Med Chile. 2004; 132: 1173-8.
49. Barbolla RE, Centron D, Di Martino A, Maimone S, Salgueira
C, Famiglietti A. Identification of an epidemic carbapenem-
resistant Acinetobacter baumannii strain at hospitals in Bue-
nos Aires City. Diag Microbiol Infect Dis. 2003; 45: 261-4.
50. Sader HS, Jones RN, Gales AC, SilvaJB, Pignatari AC.
SENTRY antimicrobial surveillance program report: Latin
America and Brazilian results for 1997 through 2001. Braz J
Infect Dis. 2004; 8: 25-79.
51. Álvarez C, Cortés J, Arango A, Correa C, Leal A, GREBO.
Resistencia antimicrobiana en unidades de cuidado intensivo
de Bogotá, Colombia, 2001-2003. Revista de Salud Pública
[en línea] 2006, 8: [fecha de consulta: 12 de marzo de 2011]
Disponible en: http://redalyc.uaemex.mx/redalyc/src/inicio/
ArtPdfRed.jsp?iCve=42289908
52. Leal AL, Eslava J, Álvarez C, Buitrago G, Méndez M, GREBO.
Canales endémicos y marcadores de resistencia bacteriana, en
instituciones de tercer nivel de Bogotá, Colombia. Revista de
Salud Pública. 2006; 859-70. Disponible en: http://redalyc.
uaemex.mx/redalyc/src/inicio/ArtPdfRed.jsp?iCve=4228
9906
53. Espinal PA, Mantilla JR, Saavedra CH, Leal AL, Alpuche C,
Valenzuela EM. Epidemiología molecular de infección
nosocomial por Klebsiella pneumoniae productora de â-
lactamasas de espectro extendido. Biomedica. 2004; 24: 252-
61.
54. Mantilla JR, Valenzuela EM, Gil CA, Leal AL. Caracteriza-
ción molecular de Klebsiella pneumoniae productora de β-
lactamasas de espectro estendido (βLEE) del tipo CTM-X-12.
Infectio. 2004; 8: 143.
55. Pinzón J, Mantilla JR, Valenzuela EM, Fernández F, Álvarez
CA, Osorio E. Caracterización molecular de aislamientos de
Acinetobacter baumannii provenientes de la unidad de que-
mados de un hospital de tercer nivel de Bogotá. Infectio. 2006;
10: 71-8.
56. Suárez CJ, Kattán JN, Guzmán AM, Villegas MV. Mecanis-
mos de resistencia a carbapenems en P. aeruginosa,
Acinetobacter y Enterobacteriaceae y estrategias para su
prevención y control. Infectio. 2006; 10: 85-93. 
57. Gómes AR, Sánches I, Aires De Sousa M, Castañeda E, De
Lencastre H. Molecular epidemiology of methicillin-resistant
Staphylococcus aureus in Colombian hospitals: Dominance
of a single unique multidrug-resistant clone. Microb Drug
Resist. 2001; 7: 23-32.
58. Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H,
Spratt BG. The evolutionary history of methicillin-resistant
Staphylococcus aureus (MRSA). Proc Natl Acad Sci USA.
2002; 99: 7687-92.
59. Sá-Leão R, Santos I, Dias D, Peres I, Barros R, Lencastre H.
Detection of an archaic clone of Staphylococcus aureus with
low-level resistance to methicillin in a pediatric hospital in
Portugal and in international samples: relics of a formerly
widely disseminated strain? J Clin Micorbiol. 1999; 37: 1913-
20.
60. Deshpande LM, Fritsche TR, Jones RN. Molecular epide-
miology of selected multidrug-resistant bacteria: a global
report from the SENTRY Antimicrobial Surveillance Program.
Diagn Microbiol Infect Dis. 2004; 49: 231-6.
61. Gruteke P, Goessens W, Gils J, Peerbooms N, Lemmens-den
Toom, M Santen-Verheuvel, et al. Patterns of resistance
associated with integrons, the extended-spectrum lactamase
SHV-5 gene, and a multidrug efflux pump of Klebsiella
pneumoniae causing a nosocomial outbreak. J Clin Microbiol.
2000; 41: 1161-6.
62. Martins-Loureiro M, Aguiar de Moraes B, Lorenzato-Furtado
de Mendonça V, Rocha-Quadra MR. Epidemiología molecular
de cepas de Klebsiella pneumoniae productoras de α-
lactamasas de espectro extendido aisladas de pacientes neonatos
en una unidad de cuidados intensivos involucrados en casos
de infección hospitalaria en Río de Janeiro. Brasil Rev Latinoam
Microbiol. 2001; 43: 88-95.
